Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,541Revenue $M147Net Margin (%)-18.2Z-Score6.6
Enterprise Value $M8,270EPS $-0.6Operating Margin %-22.3F-Score3
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-25.4Higher ROA y-yY
Price/Book32.910-y EBITDA Growth Rate %0Quick Ratio7.2Cash flow > EarningsY
Price/Sales39.45-y EBITDA Growth Rate %7.4Current Ratio7.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-4.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-11.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M119ROI % (ttm)-13.6Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISJoel Greenblatt 2014-12-31 Buy $36.46 - $65.09
($49.54)
$ 71.7645%New holding, 8745 sh.8,745
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 71.76128%Sold Out0
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 71.76128%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 71.7649%New holding, 45251 sh.45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 71.7649%New holding, 5539 sh.5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 71.76704%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 71.76679%New holding, 22300 sh.22,300
ISISJean-Marie Eveillard 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 71.76657%Sold Out0
ISISJean-Marie Eveillard 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 71.76719%New holding, 100000 sh.100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 71.76719%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 71.76623%New holding, 16100 sh.16,100
ISISJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 71.76596%Sold Out0
ISISJean-Marie Eveillard 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 71.76501%New holding, 50000 sh.50,000
ISISKen Fisher 2008-12-31 Sold Out $10.37 - $15.82
($12.96)
$ 71.76454%Sold Out0
ISISKen Fisher 2008-09-30 Buy $14.24 - $19.08
($16.9)
$ 71.76325%New holding, 10050 sh.10,050
ISISJean-Marie Eveillard 2007-12-31 Sold Out $15.4 - $17.69
($16.7)
$ 71.76330%Sold Out0
ISISJean-Marie Eveillard 2007-09-30 Buy $9.74 - $14.97
($12.1)
$ 71.76493%New holding, 25000 sh.25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ISIS Joel Greenblatt 2014-12-318,7450.010New Buy
Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WENDER JOSEPH HDirector 2015-03-02Sell7,000$65.976.35view
WENDER JOSEPH HDirector 2015-02-12Sell10,000$62.1512.89view
CROOKE STANLEY TChairman and CEO 2015-01-27Sell11,000$72.93-3.8view
CROOKE STANLEY TChairman and CEO 2015-01-16Sell9,054$67.963.24view
PARSHALL B LYNNECOO & Secretary 2015-01-16Sell4,093$67.963.24view
Monia Brett PSVP, Antisense Drug Discovery 2015-01-16Sell1,534$67.963.24view
HOUGEN ELIZABETH LSVP, Finance & CFO 2015-01-16Sell1,291$67.963.24view
O'NEIL PATRICK R.SVP, Legal & General Counsel 2015-01-16Sell1,291$67.963.24view
BENNETT C FRANKSVP, Antisense Research 2015-01-16Sell1,518$67.963.24view
Geary Richard SSVP, Development 2015-01-16Sell1,543$67.963.24view

Press Releases about ISIS :

    Quarterly/Annual Reports about ISIS:

    News about ISIS:

    Articles On GuruFocus.com
    Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
    Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
    Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
    Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
    Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
    Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 


    More From Other Websites
    FBI: No Pattern for ISIS Sympathizers in U.S. Mar 04 2015
    Cramer's guide: Best stocks in a bearish market Mar 04 2015
    Junior U.K. Merger Bankers Get 70% Bonus Jump, Survey Shows Mar 04 2015
    Roche's Avastin Gets Positive Opinion for Cervical Cancer - Analyst Blog Mar 02 2015
    Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog Mar 02 2015
    Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Mar 02 2015
    Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Mar 02 2015
    Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 02 2015
    Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog Mar 02 2015
    Company News for March 02, 2015 - Corporate Summary Mar 02 2015
    Horizon Pharma Beats on Q4 Earnings, Lifts 2015 Guidance - Analyst Blog Mar 02 2015
    Isis Reports Financial Results and Highlights for 2014 Mar 02 2015
    Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx Mar 02 2015
    Isis beats Street 4Q forecasts Feb 27 2015
    Isis beats Street 4Q forecasts Feb 27 2015
    ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant... Feb 27 2015
    Isis Reports Financial Results and Highlights for 2014 Feb 27 2015
    Q4 2014 Isis Pharmaceuticals Inc Earnings Release - Before Market Open Feb 27 2015
    Is There An Upside For Isis Pharmaceutical Shares? Feb 26 2015
    Can Isis Pharmaceuticals (ISIS) Beat Earnings this Season? - Analyst Blog Feb 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK